Daniel Walcher
Overview
Explore the profile of Daniel Walcher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
586
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Weinmann K, Werner J, Koenig W, Rottbauer W, Walcher D, Kessler M
Biomolecules
. 2019 Nov;
9(11).
PMID: 31731547
Immunoadsorption and subsequent administration of intravenous immunoglobulin (IVIG) have shown beneficial effects on cardiac function and symptoms in patients with dilated cardiomyopathy. Biomarkers play an emerging role in disease monitoring...
2.
Kramer L, Brettschneider J, Lennerz J, Walcher D, Fang L, Rosenbohm A, et al.
Sci Rep
. 2018 Nov;
8(1):16594.
PMID: 30413735
Cardiomyopathies with intracellular inclusions are a distinct subset of cardiomyopathies whereas basophilic degeneration (BD) of the heart describes inclusions in cardiomyocytes of the aging heart, which have not yet been...
3.
Weinmann K, Werner J, Koenig W, Rottbauer W, Walcher D, Kessler M
Biomolecules
. 2018 Nov;
8(4).
PMID: 30400209
Background: Immunoadsorption and intravenous immunoglobulin (IVIG) administration may have beneficial effects in patients with dilated cardiomyopathy with end-stage heart failure. We investigated the effect of immunoadsorption with subsequent IVIG administration...
4.
Buckert D, Markovic S, Kunze M, Wohrle J, Rottbauer W, Walcher D
Clin Case Rep
. 2017 Nov;
5(11):1807-1810.
PMID: 29152276
The MitraClip NT™ system for the treatment of severe mitral valve regurgitation is effective and safe - even for patients suffering from cardiogenic shock. The use of an intra-aortic balloon...
5.
Seeger J, Muller P, Gonska B, Scharnbeck D, Markovic S, Walcher D, et al.
J Invasive Cardiol
. 2017 Apr;
29(4):145-150.
PMID: 28368846
Aims: To compare early device success, procedural success, and 30-day safety endpoint according to the new Mitral Valve Academic Research Consortium criteria (MVARC) in severe primary and secondary mitral regurgitation...
6.
Markovic S, Dragomir S, Walcher D, Bernhardt P, Imhof A, Rottbauer W, et al.
Coron Artery Dis
. 2016 Jun;
27(7):561-5.
PMID: 27244371
Objectives: Data on multiple bioresorbable vascular scaffolds (BVS) for the treatment of coronary lesions are limited. We compared clinical results after implantation of single or multiple BVS for the treatment...
7.
Faber K, Bullinger L, Ragu C, Garding A, Mertens D, Miller C, et al.
J Clin Invest
. 2012 Dec;
123(1):299-314.
PMID: 23202735
Aberrant expression of the homeodomain transcription factor CDX2 occurs in most cases of acute myeloid leukemia (AML) and promotes leukemogenesis, making CDX2, in principle, an attractive therapeutic target. Conversely, CDX2...
8.
Vasic D, Walcher D
Int J Inflam
. 2012 Jul;
2012:932725.
PMID: 22762010
Atherosclerosis is well known as an inflammatory disease that can lead to clinical complications such as heart attack or stroke. C-peptide as a cleavage product of proinsulin is in the...
9.
Vasic D, Walcher D
Mediators Inflamm
. 2012 May;
2012:858692.
PMID: 22547909
Diabetes type 2 and insulin resistance are the risk factors for cardiovascular disease. It is already known that atherosclerosis is an inflammatory disease, and a lot of different factors are...
10.
Vasic D, Spyrantis A, Durst R, Bach H, Vogt S, Rottbauer W, et al.
Mol Cell Endocrinol
. 2012 Jan;
351(2):337-41.
PMID: 22269094
Background: Elevated levels of C-peptide have been found in patients with insulin resistance and early type 2 diabetes. These patients are at greater risk to develop micro- and macrovascular complications....